Other Headlines

The medical community pays tribute to a dedicated crew.
Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.
GI monitoring device promises to speed the evaluation and treatment of GI motility disorders.
The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.
Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.

Have News for Us?

Submit your news on the industry, people, or companies.

Forward to a Friend

More People & Company Headlines

Ceremony and Fund for Families of MedEvac Helicopter Crash The medical community pays tribute to a dedicated crew.

Ingestible Device Monitors GI Tract on the Go GI monitoring device promises to speed the evaluation and treatment of GI motility disorders.

Interview with Beth Bukata, Assistant Director of Communications for ASTRO DOTmed discusses the American Society for Therapeutic Radiation Oncology (ASTRO) program for public awareness with ASTRO's assistant director of communications, Beth Bukata.

iBrain Could Predict Drug Side Effects by Measuring Brainwaves A cell phone sized gadget could help predict drug side effects while even saying who's your twin -- just by recording brainwaves during sleep. Welcome to iBrain.

Nationwide Opens New Service Division Nationwide Imaging Services is now operating a new servicing and installation division, Nationwide Medical Equipment Services, LLC.

Stryker to Spend Almost $100 Million in New Acquisitions Stryker picks up Calif. software company OtisMed, and acquires assets behind Sonopet's ultrasonic aspirators.

The "Ratings Push" Is on That Will Choose The DOTmed 100 for 2010 -- The DOTmed 100 is a peer-evaluation program, so it's one of the truest measures of a company's commitment to integrity and customer satisfaction

Pacific Medical, LLC Expands Their Repair Facility Satisfied biomed customers and continued growth led to the move.

Genesis Magnet Services Celebrates Ten Years in Business A decade of MR quality from the independent service organization.

How Will Medicare Reform Impact Providers? A DOTmed Business News columnist comments on CMS and reform issues.

Endosense

Experimental Catheter Ablation Device Provides Tactile Feedback

by Lynn Shapiro, Writer
Geneva, Switzerland-Medical device start-up, Endosense, has developed a catheter ablation device for atrial fibrillation, which for the first time, will provide physicians with the tactile feedback they need to accurately measure the contact force between the catheter and the beating heart wall.

The experimental device, called the TactiCath, uses a proprietary fiber optics technology to precisely measure the contact force during a catheter ablation procedure, so doctor's won't have to guess, Eric Le Royer, president and chief executive officer of Endosense tells DOTmed News.

"One of the major challenges with the catheters used today is you don't know if it is touching the heart," LeRoyer says. "It's like trying to sew with no fingers." Le Royer adds, "We're providing a new sense of touch so doctors know what the force at the distal end of the catheter is, improving both safety and efficacy." Le Royer says that "until now, the positioning of the catheter was balancing act. When there's not enough contact force, the defibrillator is ineffective and when there is too much contact force, the catheter tip may perforate the heart wall.

The TactiCath-expected to win approval in the first part of 2009-- is now undergoing clinical trials in Europe. So far, the TactiCath has been tested on 10 patients. Researchers plan to complete testing of 70 patients to win regulatory approval throughout Europe, before beginning trials in the US.

Patients can live with arterial fibrillation for many years, but they are looking desperately to find solutions to the problem as the condition triggers stroke and heart failure, Le Royer says.

Currently, patients with AF have two treatment options: anti-arrhythmia drugs and beta-blockers, which only provide effectiveness 40 percent of the time; or invasive ablation surgery, he says.

TactiCath is less invasive and is the same size as standard catheters. It is a high-end, 8.5F sheath-compatible, open irrigated, steerable ablation catheter that seamlessly integrates Endosense's proprietary "touch" fiber optic sensor technology in the catheter tip. During the procedure, physicians thread the TactiCath through the patient's groin area to the upper chamber of the heart.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

Please Send us your Comments.

Printable Story
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2009 DOTmed.com, Inc.
ALL RIGHTS RESERVED